Evaluating GLP-1 Receptor Agonist Semaglutide in Phase 3 Settings for Alzheimer Disease: The EVOKE Trials
Topline results of the EVOKE and EVOKE+ studies of semaglutide will be presented at the 2025 Clinical Trials on Alzheimer’s Disease Conference, held December 1-4, in San Diego, California.
Welcome to NeurologyLive®'s Clinical Trial in Focus! Every month, an ongoing clinical trial in the landscape of neurology is featured, highlighting the design of the study, the targeted patient population, the enrollment criteria, the primary and secondary end points, and its potential implications for clinical care. This month’s spotlight is the phase 3 EVOKE trials (EVOKE, NCT04777396; and EVOKE+, NCT04777409) investigating the potential of semaglutide (Ozempic; Novo Nordisk), a glucagon-like peptide-1 (GLP-1) receptor agonist used for diabetes and weight loss, to slow cognitive decline in patients with early